BioGeometry closes Series A+ for AI-driven drug development
China Life Capital leads the financing as BioGeometry extends its work from molecular models to cell-level biology.
BioGeometry announced a Series A+ round on October 28, 2026, led by China Life Capital. The Shanghai Biomedical Innovation and Translation Fund, Guokai Kechuang, Real Power Capital, Guofang Chuangtou and Fortune Capital also backed the financing.
The company said its Series A family of rounds had raised more than $100 million in total. The amount attributable to this A+ round was not disclosed.
The financing supports a broader biological modelling approach: GeoFlow addresses molecular interactions, while GeoCell extends that work toward cellular systems. BioGeometry combines this research with automated experiments and its own drug-development programmes, linking AI-generated designs to laboratory validation.
Use of funds
Develop GeoFlow and GeoCell models
Expand automated laboratories
Advance proprietary drug programmes